Navigation Links
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Date:1/29/2009

n patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act; the tender of a majority of the outstanding shares of common stock of Indevus; the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and currency exchange rate fluc
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an emphasis ... announces that Company management will participate in the upcoming ... March 8-11, 2015 at the Ritz Carlton Laguna Niguel ... Jennifer Simpson , PhD, MSN, CRNP, Delcath,s interim President ...
(Date:3/2/2015)... NORTH HOLLYWOOD, Calif. , March 2, 2015 ... improving the quality of life of myeloma patients ... once again declared the month of March to ... IMF first established March as Myeloma Awareness Month ... information about the disease through local community events, ...
(Date:3/2/2015)... DUBLIN , Mar. 02, 2015 Research ... announced the addition of the "Lopinavir - ... , Imagine having your own ... of a button. Used by the ... over 10 years, these searches are the benchmark ...
Breaking Medicine Technology:Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3International Myeloma Foundation Declares March "Myeloma Awareness Month" 2International Myeloma Foundation Declares March "Myeloma Awareness Month" 3Global Comprehensive Lopinavir Patent Search Online Portal 2015 2
... 4, 2011 WebMD Health Corp. (Nasdaq: WBMD ... deliver a presentation at the UBS 21st Annual Global Healthcare ... ET. Investors, analysts and the general public are ... presentation over the Internet.  The broadcast can be accessed at ...
... K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a ... informed by Hologic, Inc. that the U.S. Food and ... injection).  Makena, commonly referred to as "17P," is the ... risk of preterm birth in women with a singleton ...
Cached Medicine Technology:FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 3FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 4FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 5FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 6FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 7FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 8FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 9FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 10FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 11FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 12
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... Recovery at Recovery Unplugged™—will be delivering a plenary ... Singer/Songwriter's Perspective on the Art of Healing and ... Disorders (NCAD) and Behavioral Healthcare Executive Summit (BHES).     ... name, Mr. Supa’s songs have been recorded by ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The ... grow at a CAGR of 6.1% to reach ... 2014. , Factors such as advantages of ... healthcare costs owing to minimally invasive surgeries and ... population are driving the global minimally invasive surgical ...
(Date:3/2/2015)... DC (PRWEB) March 02, 2015 Atlantic ... publication of AIS’s Directory of Health Plans: 2015 ... resource available on the U.S. health plan market, with ... in the United States. , Available as a ... Summary” of enrollment trends in quick-view tables and charts, ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 In light ... of anticoagulant Xarelto (rivaroxaban) tablets, Ford & ... may be helpful for future users, but may come ... injuries from taking the drug. The FDA has now ... under Adverse Reactions on Xarelto's label. The term “cytolytic ...
(Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
Breaking Medicine News(10 mins):Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3
... finds , WEDNESDAY, Feb. 17 (HealthDay News) -- Good ... improve their odds of staying healthy: baked rhubarb may ... garden rhubarb for 20 minutes dramatically boosted levels of ... polyphenols selectively kill or prevent the growth of cancer ...
... Rural areas tend to fare worse than urban locales, ... -- Want to know how healthy your county is? ... ranking of nearly every county in the nation shows ... on where they live. , Researchers from University of ...
... , GREENBRAE, Calif. , Feb. 17 ... of transformational media, announced today the release of Sound Sanctuaries ... Malkin . , Designed to help listeners experience deep inner peace ... moving music by Malkin that he says will "awaken the spirit ...
... N.C. , Feb. 17 MedCath Corporation (Nasdaq: ... they have entered into a definitive agreement to sell substantially ... David,s Healthcare Partnership, L.P. ("St. David,s"). The transaction is expected ... to customary closing conditions and regulatory requirements. , The sale ...
... , ... Services marked the start of 2010 with the official launch of a new state-of-the-art ... industries, this latest addition to the Almac services portfolio is set to revolutionise the ... ...
... MyNursingUniforms ... nursing uniform store. , ... February 17, 2010 -- MyNursingUniforms (MNU), a leader in online retail for nursing uniforms and ... , ,MNU made the expansion to their online store in both the shoe and medical ...
Cached Medicine News:Health News:County-By-County Report Sizes Up Americans' Health 2Health News:County-By-County Report Sizes Up Americans' Health 3Health News:New CD Collections Promise to Create a Sound Sanctuary in Your Home, Office, or Car 2Health News:MedCath Enters Definitive Agreement To Sell Heart Hospital of Austin 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 3Health News:MyNursingUniforms Adds Skechers Brand Name Shoes and Scrubs to Store 2
... The electronic, motorized ... for all applications of ... and hard specimens in ... labs. These instruments display ...
... Leica RM2255 rotary microtome, designed for ... and resin-embedded specimens, offers a broad ... research histology laboratory. This microtome meets ... a compact, fully motorized/electronic microtome for ...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user....
... system for specimen surface preparation is the ... attachment Leica SP2600. ,Ultramilling is often a ... microtomy in sample preparation. Especially with difficult ... located side by side in one specimen ...
Medicine Products: